EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS- A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
Abstract
Authors
S Marbaix H Vandenberghe L Van Gaal